2024
Prostate-specific antigen screening for prostate cancer: Diagnostic performance, clinical thresholds, and strategies for refinement
Sundaresan V, Smani S, Rajwa P, Renzulli J, Sprenkle P, Kim I, Leapman M. Prostate-specific antigen screening for prostate cancer: Diagnostic performance, clinical thresholds, and strategies for refinement. Urologic Oncology Seminars And Original Investigations 2024 PMID: 39019723, DOI: 10.1016/j.urolonc.2024.06.003.Peer-Reviewed Original ResearchProstate specific antigenProstate cancerPSA-based prostate cancer screeningDiagnostic performanceProstate specific antigen densityProstate specific antigen velocityLow-grade prostate cancerProstate-specific antigen screeningFree prostate specific antigenTreatment of prostate cancerProstate cancer screeningClinical action thresholdsProstate volumeAntigen screeningMalignant cellsSpecific antigenCancer screeningScreening biomarkerProstateClinical roleTest characteristicsCancerClinical applicationClinical thresholdEarly detection
2023
Cytologic evaluation of upper urinary tract specimens: An institutional retrospective study using The Paris System for Reporting Urine Cytology second edition with histopathologic follow‐up
Khajir G, Sun T, Wang H, Sprenkle P, Adeniran A, Cai G, Levi A. Cytologic evaluation of upper urinary tract specimens: An institutional retrospective study using The Paris System for Reporting Urine Cytology second edition with histopathologic follow‐up. Cytopathology 2023, 35: 235-241. PMID: 37916579, DOI: 10.1111/cyt.13328.Peer-Reviewed Original ResearchHigh-grade urothelial carcinomaLow-grade urothelial carcinomaUpper urinary tractUrothelial carcinomaUrinary tractCytologic evaluationCytology specimensInstitutional retrospective studyParis SystemHigh-grade malignancyAtypical urothelial cellsCytologic categoriesRetrospective studyInstitutional databaseCytological diagnosisUrinary cytopathologyHistopathologicMalignant cellsBenign casesUrothelial cellsTPS categoryCarcinomaReporting systemTractAUC